Curasight A/S (NGM: CURAS)

Sweden flag Sweden · Delayed Price · Currency is SEK · Price in DKK
9.04
-0.26 (-2.80%)
At close: Jan 24, 2025
-53.16%
Market Cap 295.93M
Revenue (ttm) n/a
Net Income (ttm) -48.98M
Shares Out 20.68M
EPS (ttm) -2.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,752
Average Volume 5,717
Open 9.04
Previous Close 9.30
Day's Range 9.04 - 9.68
52-Week Range n/a
Beta 0.11
RSI 47.21
Earnings Date Feb 20, 2025

About Curasight

Curasight A/S, a biotech company, develops treatment of cancer. The company exploits a novel Positron Emissions Tomography (PET) imaging platform that targets the urokinase-type plasminogen activator receptor (uPAR). It develops uTRACE for enhanced evaluation of cancer disease across several cancer types has been confirmed in multiple phase II clinical trials; and uTREAT, a uPAR targeted radionuclide therapy is using uTRACE together with radiation therapy to irradiate cancer with limited irradiation of healthy tissue. The company focuses on gen... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2013
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol CURAS
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

There is no news available yet.